MARINOL (dronabinol) by Ascentage Pharma is cns, including central sympathomimetic activity. First approved in 1985.
Drug data last refreshed Just now · AI intelligence enriched 1w ago
MARINOL (dronabinol) is a synthetic cannabinoid oral capsule approved in 1985 that acts on CNS cannabinoid receptors with central sympathomimetic activity. It is indicated for chemotherapy-induced nausea/vomiting and appetite stimulation in HIV/AIDS patients. The mechanism involves modulation of cannabinoid receptors in neural tissues to produce therapeutic effects.
Product is in late lifecycle with minimal commercial momentum; brand team likely focused on retention and managed decline rather than expansion.
CNS, including central sympathomimetic activity. Cannabinoid receptors have been discovered in neural tissues. These receptors may play a role in mediating the effects of dronabinol.
Cannabinoid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Dronabinol for Agitation in Dementia Crossover Trial
Dronabinol for Post-operative Pain After Lumbar Fusion
A RCT Comparing Dronabinol to a Placebo for Post-operative Pain in Total Joint Arthroplasty
Investigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
Worked on MARINOL at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on MARINOL represents a late-career or defensive portfolio assignment with limited growth trajectory; roles emphasize maintaining existing relationships and managing market decline. This product suits professionals seeking stable maintenance roles or transition opportunities rather than high-growth career acceleration.